1136 related articles for article (PubMed ID: 17291930)
1. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
2. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
3. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
[TBL] [Abstract][Full Text] [Related]
4. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
Gurbel PA; Antonino MJ; Bliden KP; Dichiara J; Suarez TA; Singla A; Tantry US
Platelets; 2008 Dec; 19(8):595-604. PubMed ID: 19012177
[TBL] [Abstract][Full Text] [Related]
5. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Gurbel PA
Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
[TBL] [Abstract][Full Text] [Related]
6. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.
Antonino MJ; Mahla E; Bliden KP; Tantry US; Gurbel PA
Am J Cardiol; 2009 Jun; 103(11):1546-50. PubMed ID: 19463513
[TBL] [Abstract][Full Text] [Related]
8. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
[TBL] [Abstract][Full Text] [Related]
9. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
12. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
13. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
Gurbel PA; Samara WM; Bliden KP
Platelets; 2004 Mar; 15(2):95-9. PubMed ID: 15154601
[TBL] [Abstract][Full Text] [Related]
14. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
[TBL] [Abstract][Full Text] [Related]
15. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
Tang FK; Lin LJ; Hua N; Lu H; Qi Z; Tang XZ
Chin Med J (Engl); 2012 Feb; 125(4):631-8. PubMed ID: 22490487
[TBL] [Abstract][Full Text] [Related]
16. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
[TBL] [Abstract][Full Text] [Related]
17. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
[TBL] [Abstract][Full Text] [Related]
18. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Barrera Ramírez C; Sabaté M; Fernandez C; Hernández-Antolín R; Escaned J; Alfonso F; Macaya C
J Invasive Cardiol; 2004 Apr; 16(4):169-74. PubMed ID: 15152138
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Gurbel PA; Bliden KP; Hiatt BL; O'Connor CM
Circulation; 2003 Jun; 107(23):2908-13. PubMed ID: 12796140
[TBL] [Abstract][Full Text] [Related]
20. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.
Gurbel PA; Bliden KP; Guyer K; Aggarwal N; Tantry US
Thromb Res; 2007; 119(5):563-70. PubMed ID: 16806409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]